asimadoline (ONO-3951) / Tioga Pharma - LARVOL DELTA

Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS). (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Tioga Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open

Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS). (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Tioga Pharmaceuticals

New P2 trial

The Utility of Peripherally Restricted Kappa-Opioid Receptor Agonists for Inhibiting Below-Level Pain after Spinal Cord Injury in Mice. (PubMed, Neuroscience) - "Asimadoline and ICI-204448 are believed to be peripherally restricted KOR agonists withlimited access to the CNS...In conclusion, systemic administration of ICI-204448 achieved SCI pain inhibition at doses that did not induce notable side effects and attenuated DRG neuronal excitability which may partly contribute to its pain inhibition. These findings suggest that peripherally restricted KOR agonists may be useful for treating SCI pain, but the therapeutic window must be carefully examined."

Journal • Preclinical • CNS Disorders • Immunology • Orthopedics • Pain

Opioids in the Treatment of Chronic Idiopathic Diarrhea in Humans-A Systematic Review and Treatment Guideline. (PubMed, J Clin Med) - "Generally, studies reported a reduction in stool frequency and an increase in transit time during treatment with the opioid receptor agonists loperamide, asimadoline, casokefamide, and codeine compared with placebo. Most trials included few participants, and further evidence is needed from larger, prospective studies. Likewise, consensus is needed to standardize endpoints for stool frequency, transit time, and consistency to conduct future meta-analyses on opioids in management of chronic idiopathic diarrhea."

Journal • Review • Gastrointestinal Disorder • Pain

Topical κ-Opioid Receptor Agonist Asimadoline Improves Dermatitis in a Canine Model of Atopic Dermatitis. (PubMed, Exp Dermatol) - "Overtime the placebo scores increased while the active ingredient showed decrease after first 3 weeks. It is concluded that this approach is promising in dogs with AD and longer studies with more frequent application may be beneficial."

Journal • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: A systematic review and meta-analysis. (PubMed, Medicine (Baltimore)) - "This is the first meta-analysis to examine the use of opioid receptor modulators in IBS, and few adverse events were reported in the available trials. Compared with the control group, eluxadolin has a better effect in improving IBS global symptoms and abdominal pain and has statistical significance and showed a low rate of constipation development in IBS patients in comparison with known effects of other opioid receptor modulators. However, current findings are based on a considerably limited evidence base with marked heterogeneity. Future studies should aim to identify subpopulations of patients with IBS and need to evaluate the long-term safety of these therapies.PROSPERO registration number: CRD42020141597."

Journal • Retrospective data • Review • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain

Can we teach old drugs new tricks? - Repurposing of neuropharmacological drugs for inflammatory skin diseases. (PubMed, Exp Dermatol) - "Moreover, since numerous drugs have been evaluated for various CNS diseases, some failed and some approved, this resource should be exploited for repurposing as anti-inflammatory drugs for topical application, e.g. cannabidiol, fingolimod or asimadoline. Finally, a screening algorithm is shared which gives direct evidence of links between drug and inflammatory skin diseases."

Journal • Acne Vulgaris • Atopic Dermatitis • CNS Disorders • Dermatitis • Dermatology • Immunology • Psoriasis